Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 1.18
PTN's Cash to Debt is ranked lower than
58% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. PTN: 1.18 )
Ranked among companies with meaningful Cash to Debt only.
PTN' s Cash to Debt Range Over the Past 10 Years
Min: 1.18  Med: 147.36 Max: No Debt
Current: 1.18
F-Score: 1
Z-Score: -23.25
M-Score: -5.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -426.04
PTN's ROE (%) is ranked lower than
96% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.49 vs. PTN: -426.04 )
Ranked among companies with meaningful ROE (%) only.
PTN' s ROE (%) Range Over the Past 10 Years
Min: -210.42  Med: -132.7 Max: -28.39
Current: -426.04
-210.42
-28.39
ROA (%) -141.30
PTN's ROA (%) is ranked lower than
90% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. PTN: -141.30 )
Ranked among companies with meaningful ROA (%) only.
PTN' s ROA (%) Range Over the Past 10 Years
Min: -137.01  Med: -75.2 Max: -14.01
Current: -141.3
-137.01
-14.01
ROC (Joel Greenblatt) (%) -38046.53
PTN's ROC (Joel Greenblatt) (%) is ranked lower than
99% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.24 vs. PTN: -38046.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PTN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -12348.59  Med: -595.01 Max: -92
Current: -38046.53
-12348.59
-92
Revenue Growth (3Y)(%) 276.80
PTN's Revenue Growth (3Y)(%) is ranked higher than
99% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. PTN: 276.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PTN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -26.15 Max: 276.8
Current: 276.8
-100
276.8
EBITDA Growth (3Y)(%) -33.80
PTN's EBITDA Growth (3Y)(%) is ranked lower than
89% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. PTN: -33.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PTN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.9  Med: -17.05 Max: 14.6
Current: -33.8
-64.9
14.6
EPS Growth (3Y)(%) -32.60
PTN's EPS Growth (3Y)(%) is ranked lower than
85% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. PTN: -32.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PTN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.2  Med: -22.55 Max: 5.3
Current: -32.6
-63.2
5.3
» PTN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-12)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

PTN Guru Trades in Q3 2015

Jim Simons 82,200 sh (-77.46%)
» More
Q4 2015

PTN Guru Trades in Q4 2015

Jim Simons 86,600 sh (+5.35%)
» More
Q1 2016

PTN Guru Trades in Q1 2016

Jim Simons 147,300 sh (+70.09%)
» More
Q2 2016

PTN Guru Trades in Q2 2016

Jim Simons 217,200 sh (+47.45%)
» More
» Details

Insider Trades

Latest Guru Trades with PTN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:VRML, NAS:CDNA, NAS:AIQ, OTCPK:ILIU, NAS:TEAR, OTCPK:AVDX, NAS:OPGN, OTCBB:INIS, OTCPK:EXDI, OTCPK:SEOVF, NAS:CGIX, OTCPK:PMSNF, NAS:CEMI, OTCPK:CBIS, OTCPK:MHTX, NAS:CHEK, NAS:NSPH, OTCPK:VILGF, NAS:GENE, OTCPK:VRTT » details
Traded in other countries:PTNA.Germany,
Palatin Technologies Inc is a biopharmaceutical company engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical need and commercial potential.

Palatin Technologies Inc was incorporated in Delaware in 1986. The Company is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, cachexia (wasting syndrome) and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of acute asthma, heart failure, hypertension and other cardiovascular diseases. The Company's main product in development is bremelanotide for the treatment of female sexual dysfunction. It also has drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, dermatologic diseases and inflammatory diseases. It has an exclusive global research collaboration and license agreement with AstraZeneca AB (AstraZeneca) to commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome. The Company's main competitors, includes pharmaceutical, biopharmaceutical and biotechnology companies.

Ratios

vs
industry
vs
history
EV-to-EBIT -1.09
PTN's EV-to-EBIT is ranked lower than
99.99% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.92 vs. PTN: -1.09 )
Ranked among companies with meaningful EV-to-EBIT only.
PTN' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.3  Med: -1.7 Max: 19.2
Current: -1.09
-15.3
19.2
EV-to-EBITDA -1.09
PTN's EV-to-EBITDA is ranked lower than
99.99% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.14 vs. PTN: -1.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
PTN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.4  Med: -1.7 Max: 8.8
Current: -1.09
-26.4
8.8
Current Ratio 1.88
PTN's Current Ratio is ranked lower than
64% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.48 vs. PTN: 1.88 )
Ranked among companies with meaningful Current Ratio only.
PTN' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 3.79 Max: 21.07
Current: 1.88
1
21.07
Quick Ratio 1.88
PTN's Quick Ratio is ranked lower than
58% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. PTN: 1.88 )
Ranked among companies with meaningful Quick Ratio only.
PTN' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 3.74 Max: 21.07
Current: 1.88
1
21.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.90
PTN's 3-Year Average Share Buyback Ratio is ranked lower than
71% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. PTN: -17.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PTN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -114.5  Med: -37.3 Max: -4.1
Current: -17.9
-114.5
-4.1

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -91.70
PTN's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. PTN: -91.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PTN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.2  Med: 430.5 Max: 97808.1
Current: -91.7
5.2
97808.1

More Statistics

EPS (TTM) $ -0.34
Beta1.49
Short Percentage of Float1.35%
52-Week Range $0.36 - 0.90
Shares Outstanding (Mil)85.93

Analyst Estimate

Jun16 Jun17 Jun18 Jun19
Revenue (Mil $) 51 91
EPS ($) -0.33 -0.35 -0.19 -0.07
EPS w/o NRI ($) -0.33 -0.35 -0.19 -0.07
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for PTN

Headlines

Articles On GuruFocus.com
Chuck Royce Cuts Second Largest Communications Equipement Holding Jul 07 2015 

More From Other Websites
Palatin Technologies Receives Audit Opinion with Going Concern Explanation Sep 23 2016
Palatin Technologies Receives Audit Opinion with Going Concern Explanation Sep 23 2016
PALATIN TECHNOLOGIES INC Financials Sep 23 2016
Palatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World... Sep 23 2016
Edited Transcript of PTN earnings conference call or presentation 20-Sep-16 3:00pm GMT Sep 20 2016
PALATIN TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition Sep 20 2016
Palatin Technologies, Inc. Reports Fourth Quarter And Fiscal Year 2016 Results Sep 20 2016
Palatin Technologies, Inc. Reports Fourth Quarter And Fiscal Year 2016 Results Sep 20 2016
Palatin Technologies, Inc. to Report Fourth Quarter Fiscal Year End 2016 Results; Teleconference and... Sep 14 2016
Palatin Technologies, Inc. to Report Fourth Quarter Fiscal Year End 2016 Results; Teleconference and... Sep 14 2016
Key FDA Decisions and Trial Results Expected in October Sep 08 2016
Palatin Technologies to Present at the 36th Annual Canaccord Genuity Growth Conference Aug 08 2016
Palatin Technologies Announces Closing of $9.2 Million Financing Aug 04 2016
Palatin Technologies Announces Closing of $9.2 Million Financing Aug 04 2016
Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of... Aug 04 2016
Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of... Aug 04 2016
PALATIN TECHNOLOGIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Aug 02 2016
Palatin Technologies Announces $9.25 Million Financing Aug 01 2016
Palatin Technologies Announces $9.25 Million Financing Aug 01 2016
Catalent Agreement to Commercially Supply Palatin Technologies’ New Product Jul 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)